Results 81 to 90 of about 304,742 (351)

MCT1 in Invasive Ductal Carcinoma: Monocarboxylate Metabolism and Aggressive Breast Cancer. [PDF]

, 2017
Introduction: Monocarboxylate transporter 1 (MCT1) is an importer of monocarboxylates such as lactate and pyruvate and a marker of mitochondrial metabolism.
Birbe, Ruth C., Chen, Jason, Colombo, Daniele, Cotzia, Paolo, Domingo-Vidal, Marina, Fratamico, Roberto, Johnson, Jennifer M., Lin, Zhao, Martinez-Outshoorn, Ubaldo E., Mikkilineni, Lekha, Mollaee, Mehri, Palazzo, Juan P., Tuluc, Madalina, Whitaker-Menezes, Diana, Zhan, Tingting   +14 more
core   +2 more sources

Synchronous papillary thyroid carcinoma and breast ductal carcinoma [PDF]

Journal of International Medical Research, 2020
A 48-year-old woman was admitted to our hospital with a lump in her left breast. She was diagnosed with synchronous papillary thyroid carcinoma and breast ductal carcinoma. The patient underwent four cycles of neoadjuvant chemotherapy with epirubicin and cyclophosphamide, and one cycle of docetaxel.
Heng Kong, JiXin Chen, Shou-Ching Tang
openaire   +4 more sources

Clinical significance of stratifying prostate cancer patients through specific circulating genes

Molecular Oncology, EarlyView.
We tested a specific panel of genes representative of luminal, neuroendocrine and stem‐like cells in the blood of prostate cancer patients, showing predictive value from diagnosis to late stages of disease. This approach allows monitoring of treatment responses and outcomes at specific time points in trajectories.
Seta Derderian, Edouard Jarry, Arynne Santos, Quentin Vesval, Lucie Hamel, Rafael Sanchez‐Salas, Alexis Rompré‐Brodeur, Wassim Kassouf, Raghu Rajan, Fadi Brimo, Marie Duclos, Armen Aprikian, Simone Chevalier   +12 more
wiley   +1 more source

Exosomes and their roles in the chemoresistance of pancreatic cancer

Cancer Medicine, Volume 11, Issue 24, Page 4979-4988, December 2022., 2022
Despite the development of multiple promising chemotherapeutic agents as recommended first‐line treatment for PC, the therapeutic efficacy is largely limited by unwanted drug resistance.Exploring the relation between exosomes and chemoresistance may be conducive to understanding molecular mechanisms and taking effective measures to reduce the ...
Yubin Pan, Honglin Tang, Qijun Li, Guangpeng Chen, Da Li   +4 more
wiley   +1 more source

Diagnostic pitfall in a case of ductal carcinoma-in situ with microinvasion

Journal of Cytology, 2016
We report a case of microinvasive carcinoma of the breast cytologically diagnosed as ductal carcinoma - in situ in an 80-year-old lady with a breast lump. Extensive sampling of mastectomy specimen showed ductal carcinoma in situ (DCIS). Many ducts showed
Yasmin A Momin, Medha P Kulkarni, Bhakti D Deshmukh, Kalpana R Sulhyan   +3 more
doaj   +1 more source

Response to neoadjuvant chemotherapy in early breast cancers is associated with epithelial–mesenchymal transition and tumor‐infiltrating lymphocytes

Molecular Oncology, EarlyView.
Epithelial–mesenchymal transition (EMT) and tumor‐infiltrating lymphocytes (TILs) are associated with early breast cancer response to neoadjuvant chemotherapy (NAC). This study evaluated EMT and TIL shifts, with immunofluorescence and RNA sequencing, at diagnosis and in residual tumors as potential biomarkers associated with treatment response.
Françoise Derouane, Jérôme Ambroise, Cédric van Marcke, Mieke Van Bockstal, Martine Berlière, Christine Galant, Hélène Dano, Médina Lougué, Elena Benidovskaya, Guy Jerusalem, Vincent Bours, Claire Josse, Jérôme Thiry, Aurélie Daumerie, Caroline Bouzin, Cyril Corbet, François P. Duhoux   +16 more
wiley   +1 more source

Concordance of breast cancer biomarker testing in core needle biopsy and surgical specimens: A single institution experience

Cancer Medicine, Volume 11, Issue 24, Page 4954-4965, December 2022., 2022
Retesting estrogen receptor and HER2 status provides more clinical benefit than retesting progesterone receptor status. We propose guidelines for retesting receptor profiles to aid patient care management decisions, prioritize clinical benefits, and minimize healthcare costs.
Jessica A. Slostad, Nicole K. Yun, Aimee E. Schad, Surbhi Warrior, Louis F. Fogg, Ruta Rao   +5 more
wiley   +1 more source

Changes in mRNA expression of oncogenesis driver genes in atypical ductal breast hyperplasia

Опухоли женской репродуктивной системы
Background. Atypical ductal hyperplasia is a relatively common breast lesion that increases the risk of breast cancer by 3.5 to 5 times. Genomic rearrangements underlying the development of atypical proliferative lesions and breast cancer lead to gene ...
O. V. Burmenskaya, V. V. Kometova, A. A. Smetnik, V. V. Rodionov, D. Yu. Trofimov, L. A. Ashrafyan, G. T. Sukhikh   +6 more
doaj   +1 more source

Case Report: Ductal Carcinoma in Situ Within A Granulomatous Mastitis

European Journal of Breast Health, 2018
Granulomatous lobular mastitis is a rare chronic breast disease, firstly described by Kessler and Wolloch in 1972. In this article we present a 35-yearold patient with granulomatous lobular mastitis and in situ ductal carcinoma and discuss ...
Mine Özşen, Şahsine Tolunay, M. Şehsuvar Gökgöz   +2 more
doaj   +1 more source

Invasive Ductal Carcinoma of the Breast in a Transgender Man: A Case Report

Case Reports in Oncology, 2023
There is limited literature about breast cancer in the transgender population. Very little is known about how gender-affirming hormone therapy affects their breast cancer risk.
Yujing J. Heng, Kevin J. Zhang, Monica G. Valero, Gabrielle M. Baker, Valerie J. Fein-Zachary, Michael S. Irwig, Gerburg M. Wulf   +6 more
doaj   +1 more source